← Back to Search

Dermal Filler

Dermal Filler for Chin Augmentation

N/A
Waitlist Available
Research Sponsored by Galderma R&D
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after last treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to show that Restylane Lyft with Lidocaine is effective for enhancing the chin's appearance. It targets people who want a better chin profile by using a filler that adds volume under the skin. Restylane Lyft is a hyaluronic acid filler widely used for facial augmentation, including nonsurgical rhinoplasty and chin enhancement.

Who is the study for?
This trial is for adults aged 22 or older who want to improve their chin profile through augmentation and correction of retrusion. It's not for those with allergies to hyaluronic acid gels, severe allergies like anaphylaxis, previous facial surgeries below the nose line, other aesthetic procedures in the area, or sensitivities to local anesthetics like lidocaine.
What is being tested?
The study aims to show that Restylane Lyft with Lidocaine is just as safe and effective as another FDA-approved dermal filler when used for chin enhancement. Participants will receive injections intended to augment the chin region.
What are the potential side effects?
Potential side effects may include reactions at the injection site such as redness, swelling, pain, bruising; allergic responses; and possibly lumps or asymmetry in the treated area.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after last treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after last treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary Effectiveness Objective
Secondary study objectives
Secondary Effectiveness Objective

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: New Dermal Filler for indication: Restylane Lyft with LidocaineExperimental Treatment1 Intervention
hyaluronic acid dermal filler
Group II: Active Comparator: FDA approved Dermal Filler: Juvederm Voluma XCActive Control1 Intervention
hyaluronic acid dermal filler
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Restylane Lyft with Lidocaine
2015
N/A
~160

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for chin retrusion include injectable soft tissue fillers like hyaluronic acid (HA) fillers, such as Restylane Lyft with Lidocaine. These fillers work by adding volume to the chin area, thereby enhancing its projection and contour. Hyaluronic acid is a naturally occurring substance in the body that attracts and retains water, providing immediate volume and hydration to the treated area. The inclusion of lidocaine in these fillers helps to minimize pain during the injection process. This mechanism is crucial for chin retrusion patients as it offers a minimally invasive option to improve facial symmetry and aesthetics, leading to enhanced self-esteem and satisfaction with their appearance.
Microcannula Injection of Large Gel Particle Hyaluronic Acid for Cheek Augmentation and the Correction of Age-Related Midface Contour Deficiencies.Safety and Effectiveness of VYC-15L, a Hyaluronic Acid Filler for Lip and Perioral Enhancement: One-Year Results From a Randomized, Controlled Study.

Find a Location

Who is running the clinical trial?

Galderma R&DLead Sponsor
302 Previous Clinical Trials
60,494 Total Patients Enrolled
2 Trials studying Chin Retrusion
288 Patients Enrolled for Chin Retrusion
Study DirectorStudy DirectorGalderma R&D
1,281 Previous Clinical Trials
500,328 Total Patients Enrolled

Media Library

Restylane Lyft with Lidocaine (Dermal Filler) Clinical Trial Eligibility Overview. Trial Name: NCT05777759 — N/A
Chin Retrusion Research Study Groups: New Dermal Filler for indication: Restylane Lyft with Lidocaine, Active Comparator: FDA approved Dermal Filler: Juvederm Voluma XC
Chin Retrusion Clinical Trial 2023: Restylane Lyft with Lidocaine Highlights & Side Effects. Trial Name: NCT05777759 — N/A
Restylane Lyft with Lidocaine (Dermal Filler) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05777759 — N/A
~65 spots leftby Dec 2025